Can Air Pollution Cause Sinus Disease?

Dr. Franklyn Gergits, ENT

Short answer: Yes. A growing body of evidence links air pollution — particularly fine particulate matter known as PM2.5 — to chronic rhinosinusitis through direct mucosal injury, inflammatory cytokine activation, and disruption of the nasal mucociliary clearance system. A UK Biobank study of 367,298 participants found that long-term PM2.5 exposure increased CRS risk by 59 percent. Every microgram per cubic meter increase in PM2.5 exposure is associated with a ten percent increase in CRS-related outpatient visits. For patients in Scottsdale, Phoenix, and the greater Maricopa County area — where dust events, vehicle emissions, and seasonal wildfire smoke create a complex air quality burden — this research is directly relevant to understanding why sinus disease may be more persistent and harder to control than in lower-pollution environments.

How Air Pollution Damages the Nasal and Sinus Lining

The nasal cavity is the body’s first line of defense against inhaled particles and gases. The mucosal lining — covered by a layer of mucus and hairlike cilia — traps particles and moves them toward the throat for clearance. This mucociliary system is remarkably effective for particles of normal size. But ultrafine particles — PM2.5, defined as particles 2.5 micrometers or smaller — are small enough to penetrate deeply into the nasal mucosa and in some cases reach the lower airways entirely, bypassing the mechanical defenses.

Once deposited on the sinus mucosa, PM2.5 particles trigger a cascade of inflammatory responses. A 2026 study of 634 patients identified a specific PM2.5-associated inflammatory endotype of CRS characterized by joint elevations of IL-2, IL-5, IL-7, IL-13, IL-12/23p40, and IL-21 — a mixed type 2 and type 3 cytokine pattern that is clinically distinct from other CRS subtypes. Critically, different pollutants drive different inflammatory signatures: traffic-related nitrogen dioxide is associated with elevated type 2 cytokines (IL-4, IL-5, IL-13), while benzene and lead drive non-type 2 inflammatory profiles. This matters because standard intranasal corticosteroid therapy — the mainstay of CRS medical management — targets type 2 inflammation most effectively. Patients exposed primarily to benzene and lead may have sinus disease that does not respond to the standard approach, not because treatment is inadequate, but because the pollutant driving their disease activates a different pathway entirely.

One of the most striking statistics in this literature: patients with high PM2.5 exposure had a 94 percent rate of CRS with nasal polyps compared with 69 percent in the low-exposure group. For patients in the Phoenix and Scottsdale area living with the region’s air quality burden, this is a clinically significant finding — nasal polyp disease is harder to treat, more likely to recur after surgery, and more likely to require biologics than CRS without polyps.

A JAMA Otolaryngology case-control study found that each standard deviation increase in traffic-related nitrogen dioxide was associated with a 132 percent rise in CRS odds (aOR 2.32) — with benzene (aOR 2.15) and lead (aOR 3.48) also independently significant.

What This Means Specifically for the Phoenix and Scottsdale Area

Patients living in Scottsdale, Phoenix, Tempe, Mesa, Chandler, Gilbert, and the broader Maricopa County area face a specific combination of air quality challenges that distinguishes their environmental exposure from most other parts of the country.

Dust storms and haboobs — the dramatic wall-of-dust events that sweep across the Phoenix metro area, particularly in the pre-monsoon season — carry enormous quantities of coarse and fine particulate matter, including desert soil particles, biological material, and allergens. A single haboob can dramatically spike PM10 and PM2.5 readings for hours, and the airway inflammation that follows can persist for days.

Vehicle emissions in a high-traffic basin with temperature inversions that trap pollutants at ground level contribute to chronically elevated nitrogen dioxide and ozone levels in the Phoenix metro area, particularly during summer months when the inversion layer is most stable.

Wildfire smoke from California, Colorado, and New Mexico increasingly affects Arizona air quality during summer and fall fire seasons, with PM2.5 spikes that can last for days to weeks and that carry combustion byproducts — polycyclic aromatic hydrocarbons, carbon particles, and other compounds — that are more biologically active than natural dust at equivalent concentrations.

Desert allergens combine with poor air quality to create a double insult — the allergens themselves drive type 2 inflammatory responses, while the co-exposure to pollutants amplifies allergic sensitization and lowers the threshold for allergic reactions. Research suggests that co-exposure to allergens and PM2.5 produces a more severe inflammatory response than either alone.

The Inflammatory Endotypes — Why This Matters for Treatment and Surgery

Not all CRS is driven by the same inflammatory mechanism. The traditional classification of CRS with and without nasal polyps is giving way to a more nuanced endotype model based on which cytokine pathways are dominant. The PM2.5-associated endotype — with its mixed type 2 and type 3 cytokine signature — explains why some patients in high-pollution environments have sinus disease that does not respond as well to standard intranasal corticosteroid therapy.

The impact of air pollution extends beyond causing sinus disease — it also affects outcomes after treatment. A multi-site study found that patients with higher perioperative PM2.5 exposure at the time of sinus surgery had significantly less improvement in validated sinus symptom scores after the procedure. This is a clinically important finding for patients in the Phoenix and Scottsdale area considering sinus surgery: the air quality at the time of and after your procedure may influence how well you recover. Managing environmental exposure during the perioperative period is not just a general health recommendation — it is a factor in surgical outcomes.

At the tissue level, higher ozone exposure has been associated with greater histological inflammation and increased eosinophilic aggregates and Charcot-Leyden crystals in CRS patients with nasal polyps — connecting ambient air quality directly to the severity of inflammatory disease seen under the microscope at surgery.

What You Can Do

For patients in the Scottsdale and Phoenix area whose sinus symptoms worsen during dust events, wildfire smoke episodes, or high-traffic commute periods, the environmental contribution to their disease is real and addressable — within limits. HEPA air filtration at home and in the workplace reduces indoor PM2.5 exposure meaningfully. N95 masks during outdoor dust events and wildfire smoke episodes reduce exposure by a factor of approximately 14 and have been shown to reduce hospitalizations from smoke exposure by approximately 30 percent — making masking during haboobs and smoke days a genuinely evidence-based recommendation, not just common sense. Nasal saline irrigation immediately after high-exposure outdoor activity physically removes deposited particles from the nasal mucosa before they trigger their full inflammatory response. Avoiding outdoor activity on high-AQI days — checking AQI at airnow.gov before outdoor exercise — reduces cumulative exposure.

A 2025 molecular study provides an important insight into why some patients are more vulnerable to pollution-driven sinus disease than others: PM2.5 generates reactive aldehyde compounds in the airway, and the enzyme ALDH1A1 is responsible for detoxifying these compounds and protecting mucociliary function. Patients with reduced ALDH1A1 activity — which may be genetic or environmentally acquired — experience greater mucociliary impairment from equivalent PM2.5 exposure. Research is ongoing into whether antioxidant strategies can support this detoxification pathway in susceptible patients.

None of these measures eliminate exposure entirely. The dose-response relationship between air pollution and CRS appears continuous without a clear safe threshold — meaning any reduction in exposure produces some benefit. For patients whose sinus disease is environmentally amplified, addressing the environmental component alongside the medical treatment of their underlying disease produces better and more durable outcomes than treating the inflammation in isolation.

Want to Understand More?

This post is part of the Journal of Airway Inflammation series on the Airway & Sinus Wellness Review.

→ Why Antibiotics Keep Failing Your Sinus Infection

→ Is It Possible to Have Sinusitis Without Symptoms of a Cold?

→ What Is MicroGenDX — and Why Does It Change How We Treat Sinus Infections?

→ The Final Chapter: What the Field Still Cannot See — Posterior Sinonasal Syndrome

→ Airway & Sinus Wellness Review — Full Publication

This post is part of the Journal of Airway Inflammation section of the Airway & Sinus Wellness Review.

References

1. Zhou Q, Ma J, Biswal S, et al. Air pollution, genetic factors, and chronic rhinosinusitis: a prospective study in the UK Biobank. Science of the Total Environment. 2024. HR 1.59 for long-term PM2.5 exposure; 367,298 participants.

2. Meiklejohn DA, Tummala N, Lalakea ML. Climate change, allergic rhinitis, and sinusitis. JAMA. 2025. PM2.5: 10% increase in CRS-related visits per µg/m³; 94% vs 69% CRSwNP with high exposure.

3. Martin WJ, Mirmozaffari Y, Cook LM, et al. The role of the environment and occupational exposures in chronic rhinosinusitis. Current Allergy and Asthma Reports. 2025. Environmental CRS drivers including dust, occupational exposures, wildfire smoke.

4. PM2.5-associated CRS inflammatory endotype study. Mixed type 2/type 3 cytokine signature (IL-2, IL-5, IL-13, IL-21) in 634 patients with high PM2.5 exposure. Otolaryngology–Head and Neck Surgery. 2026.

5. NO2 and CRS case-control study. Each SD increase in traffic-related NO2 associated with 132% rise in CRS odds (aOR 2.32). JAMA Otolaryngology–Head & Neck Surgery.

6. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020. Rhinology. 2020. Environmental factors in CRS pathogenesis.

7. Yang et al. JAMA Otolaryngology–Head & Neck Surgery 2026. NO2 (aOR 2.32), benzene (aOR 2.15), lead (aOR 3.48) independently associated with CRS; pollutant-specific cytokine signatures: NO2 → type 2; benzene/lead → non-type 2.

8. Lofgren et al. PM2.5-associated CRS inflammatory endotype: full cytokine panel IL-2, IL-5, IL-7, IL-13, IL-12/23p40, IL-21 (β=1.27, p<.0001 after adjustment); 634 patients. Journal of Allergy and Clinical Immunology. 2026.

9. Tullis DA, et al. Perioperative PM2.5 exposure and ESS outcomes: higher PM2.5 associated with significantly less SNOT-22 improvement post-surgery (ρ=0.26, p=.01). Multi-site study. 2024.

10. Ozone-CRSwNP histopathology study. Higher ozone exposure associated with greater tissue inflammation, eosinophilic aggregates, and Charcot-Leyden crystals in nasal polyp tissue at surgery. 2024.

11. ALDH1A1 mechanism study. PM2.5 generates reactive aldehydes impairing mucociliary clearance; ALDH1A1 detoxifies these compounds. Loss of function → increased susceptibility to pollution-driven airway disease. Journal of Clinical Investigation. 2025.

12. AAAAI 2025 work group report. N95 masks reduce PM2.5 exposure by factor of 14; reduce smoke-related hospitalizations by ~30%. Allergen-pollution co-exposure amplifies IgE switching and allergic sensitization.

About the Author

Dr. Franklyn R. Gergits, MBA, DO, FAOCO is a Board-Certified Otolaryngologist and Fellowship-Trained Otolaryngic Allergist with a Clinical Focus in Rhinology and Airway Disorders and over 30 years of clinical experience. He is the founder of the Sinus & Allergy Wellness Center of North Scottsdale, where he performs in-office balloon sinuplasty, turbinate reduction, NEUROMARK® posterior nasal nerve ablation, and Eustachian tube dilation under local anesthesia. He performed the first balloon sinuplasty in Pennsylvania and holds dual Entellus Centers of Excellence certifications. Dr. Gergits is the originator of the Posterior Sinonasal Syndrome (PSS) hypothesis — a clinical framework identifying pepsin-mediated posterior nasal mucosal injury as an upstream driver of chronic rhinosinusitis. Preprint available at Preprints.org (DOI: 10.20944/preprints202603.0858.v1). ORCID: 0009-0000-4893-6332.

SinusAndAllergyWellnessCenter.com · 480-525-8999

This content is for educational purposes only and does not constitute medical advice. If you suspect environmental exposures are contributing to your sinus symptoms, consult with a qualified otolaryngologist for a complete evaluation of potential inflammatory drivers.